Abstract:Background: The antigen processing machinery (APM) plays a critical role in generating tumor-specific antigens that can be recognized and targeted by the immune system. Proper functioning of APM components is essential for presenting these antigens on the surface of tumor cells, enabling immune detection and destruction. In many cancers, defects in APM can lead to immune evasion, contributing to tumor progression and poor clinical outcomes. However, the status of the APM in sarcomas is not well characterized, limiting the development of effective immunotherapeutic strategies for these patients. Methods: We investigated 126 patients with 8 types of bone and soft tissue sarcoma operated between 2001-2021. Tissue microarrays mapped 11 specific areas in each case. The presence/absence of APM protein was determined through immunohistochemistry. Bayesian networks were used. Results: All investigated sarcomas had some defects in APM. The least damaged component was HLA Class I subunit β2-microglobulin and HLA Class II. The proteasome LMP10 subunit was defective in leiomyosarcoma (LMS), myxoid liposarcoma (MLPS), and dedifferentiated liposarcoma (DDLPS), while MHC I transporting unit TAP2 was altered in undifferentiated pleomorphic sarcoma (UPS), gastrointestinal stromal tumor (GIST), and chordoma (CH). Among different neoplastic areas, high-grade areas showed different patterns of expression compared to high lymphocytic infiltrate areas. Heterogeneity at the patient level was also observed. Loss of any APM component was prognostic of distant metastasis (DM) for LMS and DDLPS and of overall survival (OS) for LMS. Conclusion: Sarcomas exhibit a high degree of defects in APM components, with differences among histotypes and tumoral areas. The most commonly altered APM components were HLA Class I subunit β2-microglobulin, HLA Class I subunit α (HC10), and MHC I transporting unit TAP2. The loss of APM components was prognostic of DM and OS and clinically relevant for LMS and DDLPS. This study explores sarcoma molecular mechanisms, enriching personalized therapeutic approaches.

Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets

Epigenetic determinants of fusion-driven sarcomas: paradigms and challenges

Soft tissue sarcomas: From a morphological to a molecular biological approach

Dysregulation of miRNAs in Soft Tissue Sarcomas

Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas

Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas

The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives

Omics sciences and precision medicine in sarcoma

Translational Aspects of Epithelioid Sarcoma: Current Consensus

MicroRNAs in the Pathogenesis, Prognostication and Prediction of Treatment Resistance in Soft Tissue Sarcomas

Clinical and translational implications of immunotherapy in sarcomas

Disruptions in antigen processing and presentation machinery on sarcoma

Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?

New strategies in soft tissue sarcoma treatment

Unlocking epigenetics for precision treatment of Ewing's sarcoma

Advances in molecular targeted therapy for soft tissue sarcomas

Epigenetic age acceleration is a distinctive trait of epithelioid sarcoma with potential therapeutic implications

Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype

Clinical implications and molecular features of extracellular matrix networks in soft tissue sarcomas

Clinical biomarkers in soft tissue sarcoma A comprehensive review of current soft tissue sarcoma biomarkers

Defining Which Patients Are at High Risk for Recurrence of Soft Tissue Sarcoma